Detalhe da pesquisa
1.
Favorable outcomes of DDX41-mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide.
EJHaem
; 4(4): 1212-1215, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-38024610